eLifeBiochemistryPeer-reviewed journal article
SDR enzymes oxidize specific lipidic alkynylcarbinols into cytotoxic protein-reactive species
P. Demange, E. Joly, J. Marcoux, P. R. A. Zanon, D. Listunov, P. Rulliere, C. Barthes, C. Noirot, J.-B. Izquierdo, K. Pradines, R. Hee, M. V. de Brito, M. Marcellin, R.-F. Serre, O. Bouchez, O. Burlet-Schiltz, M. C. F. Oliveira, S. Ballereau, V. Bernardes-Genisson, V. Maraval, P. Calsou, S. M. Hacker, Y. Genisson, R. Chauvin, S. Britton
Abstract
Hundreds of cytotoxic natural or synthetic lipidic compounds contain chiral alkynylcarbinol motifs, but the mechanism of action of those potential therapeutic agents remains unknown. Using a genetic screen in haploid human cells, we discovered that the enantiospecific cytotoxicity of numerous terminal alkynylcarbinols, including the highly cytotoxic dialkynylcarbinols, involves a bioactivation by HSD17B11, a short-chain dehydrogenase/reductase (SDR) known to oxidize the C-17 carbinol center of androstan-3-alpha,17-beta-diol to the corresponding ketone. A similar oxidation of dialkynylcarbinols generates dialkynylketones, that we characterize as highly protein-reactive electrophiles. We established that, once bioactivated in cells, the dialkynylcarbinols covalently modify several proteins involved in protein-quality control mechanisms, resulting in their lipoxidation on cysteines and lysines through Michael addition. For some proteins, this triggers their association to cellular membranes and results in endoplasmic reticulum stress, unfolded protein response activation, ubiquitin-proteasome system inhibition and cell death by apoptosis. Finally, as a proof-of-concept, we show that generic lipidic alkynylcarbinols can be devised to be bioactivated by other SDRs, including human RDH11 and HPGD/15-PGDH. Given that the SDR superfamily is one of the largest and most ubiquitous, this unique cytotoxic mechanism-of-action could be widely exploited to treat diseases, in particular cancer, through the design of tailored prodrugs. O_FIG O_LINKSMALLFIG WIDTH=200 HEIGHT=108 SRC="FIGDIR/small/460423v1_ufig1.gif" ALT="Figure 1"> View larger version (47K): org.highwire.dtl.DTLVardef@12daae1org.highwire.dtl.DTLVardef@12db406org.highwire.dtl.DTLVardef@1863517org.highwire.dtl.DTLVardef@7b548_HPS_FORMAT_FIGEXP M_FIG Graphical abstract C_FIG
Reproducibility ledger
Nobody has reported trying to reproduce this paper yet. Did you replicate an experiment or run the code? Your report saves the next lab a week.
Sign in to file a reproducibility report.
Related papers
- Very long chain fatty acids drive 1-deoxy-Sphingolipid toxicity
Adam Majcher, Gergely Karsai, … Thorsten Hornemann·bioRxiv·May 13, 2025
- Stereoinversion via alcohol dehydrogenases enables complete catabolism of β-1-type lignin-derived aromatic isomers
R. Kato, K. Maekawa, … E. Masai·Applied and Environmental MicrobiologyPeer-reviewed·Jun 28, 2023
- The synthetic triterpenoids CDDO-TFEA and CDDO-Me, but not CDDO, are potent BACH1 inhibitors
L. Casares, R. Moreno, … L. de la Vega·bioRxiv·Oct 29, 2021
- Dioxin-elicited decrease in cobalamin redirects hepatic propionyl-CoA metabolism to the β-oxidation-like pathway resulting in acrylyl-CoA conjugate accumulation
K. Orlowska, R. R. Fling, … T. Zacharewski·bioRxiv·Mar 24, 2021
- CYP4F2-mediated ω-hydroxylation of 1-deoxysphingolipids reveals a new hepatic detoxification pathway
Adam Majcher, Essa M. Saied, … Thorsten Hornemann·bioRxiv·May 14, 2026
- Interactive regulation between aliphatic hydroxylation and aromatic hydroxylation of thaxtomin D in TxtC, a theoretical investigation